Equity Profile

BCRX

BioCryst Pharmaceuticals, Inc.

Health CareBiotechnology$2.5B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Revenue Growth

Understanding revenue trends is crucial for assessing the company's market position and product demand.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $3 billion, it operates in the health care sector, which is increasingly important as demand for specialized medical solutions continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an EPS of -$2.98, falling short of expectations by a significant margin. The stock reacted negatively, dropping 2.21% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Market expectations are cautious following a significant EPS miss last quarter, with uncertainty surrounding revenue and product developments. Investors are closely watching for any signs of recovery or growth.

Bull Case

If BioCryst can demonstrate a strong recovery in revenue and positive updates on its product pipeline, it could restore investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to show improvement in its financials or provides disappointing guidance, the stock could face further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the product pipeline and any upcoming launches?

The market will closely evaluate any updates on new products or advancements, as these could significantly influence future revenue.

How does management plan to address the recent EPS miss and improve financial performance?

Investors will want to hear concrete strategies for recovery, as this will impact confidence in the company's leadership and direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in BioCryst's product pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect volatility and potential positive surprises.

Historical performance shows that the company has a 63% beat rate, suggesting a higher likelihood of exceeding expectations.

Recent product developments may not be fully reflected in current market sentiment.

Key Risk

If product pipeline updates indicate stronger-than-expected demand, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to recover from previous misses and provide a clear growth strategy.

Bull Confirmed If

A strong recovery in revenue growth alongside positive updates on the product pipeline would confirm the bull case.

Bear Confirmed If

Failure to improve EPS or provide a clear path to profitability would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests the stock could rise by an average of 7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of around 8.34% based on historical patterns, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected launch dates.
2Management's strategy for addressing the recent EPS miss.
3Details on revenue growth trends and market demand for products.
4Guidance on future earnings expectations and financial performance.
5Insights into competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative treatments for rare diseases....

Key Metrics to Watch

Revenue Growth

Understanding revenue trends is crucial for assessing the company's market position and product demand.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and helps investors gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BCRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

-346.07%

Avg Stock Reaction

+1.71%

Last Quarter Recap

In Q1-2026, BioCryst reported an EPS of -$2.98, falling short of expectations by a significant margin. The stock reacted negatively, dropping 2.21% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioCryst can demonstrate a strong recovery in revenue and positive updates on its product pipeline, it could restore investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to show improvement in its financials or provides disappointing guidance, the stock could face further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the product pipeline and any upcoming launches?

The market will closely evaluate any updates on new products or advancements, as these could significantly influence future revenue.

How does management plan to address the recent EPS miss and improve financial performance?

Investors will want to hear concrete strategies for recovery, as this will impact confidence in the company's leadership and direction.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a turnaround in BioCryst's product pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

The options market is pricing a significant move, indicating that traders expect volatility and potential positive surprises.

Historical performance shows that the company has a 63% beat rate, suggesting a higher likelihood of exceeding expectations.

Recent product developments may not be fully reflected in current market sentiment.

Key Risk

If product pipeline updates indicate stronger-than-expected demand, it could challenge current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on the company's ability to recover from previous misses and provide a clear growth strategy.

Bull Confirmed If

A strong recovery in revenue growth alongside positive updates on the product pipeline would confirm the bull case.

Bear Confirmed If

Failure to improve EPS or provide a clear path to profitability would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±28.46%

Historical Avg

±9.5%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±28.5% while BCRX has averaged ±9.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

53.1%

Calls (128K)P/C Ratio: 0.23Puts (28K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioCryst beats expectations, history suggests the stock could rise by an average of 7.73%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of around 8.34% based on historical patterns, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the product pipeline and expected launch dates.
2Management's strategy for addressing the recent EPS miss.
3Details on revenue growth trends and market demand for products.
4Guidance on future earnings expectations and financial performance.
5Insights into competitive positioning within the biotechnology sector.